The Amicus facility encompasses 75,000 square feet of the top three floors of a new building located on Market Street in Philadelphia. The space includes office space, as well as state-of-the-art laboratories. It’s expected to provide space for approximately 200 researchers and drug developers focused exclusively on gene therapies.
Thanks to a unique partnership between GlaxoSmithKline and Montgomery College, students who are interested in pursuing a biotech career no longer must face this crossroad. They can now have the best of both worlds – earning a respected biotech associate degree from Montgomery College all while gaining specialized, hands-on job experience on the grounds of GSK.
BioBuzz Community Thriving as Showcased in Recent Return to In-Person Events after Nearly Two-Year Hiatus
Around 200 attendees joined BioBuzz’s first gathering since pre-COVID at Brookeville Beer Farm last week, reveling in the feeling of being face-to-face with other community members of the Biohealth Capital Region after a year and a half of Zoom meetings. The event, which CRB sponsored, highlighted the importance of getting back together as a community.
The BioHealth Capital Region Forum offered many insights into the state of the industry, but the most prevalent theme was certainly big data. Panelists and keynote speakers across multiple events spoke about the importance of data in the biohealth and life sciences industry and how artificial intelligence will help the sector innovate.
Cell therapies have grown to become a prevailing field dominating new medical breakthroughs with the promise of treatments and cures for multiple diseases. The biopharma hubs of Philadelphia and Maryland have emerged as important drivers of this new wave of medicine, build on the foundation of renowned research institutes, universities, and a number of successful cell therapy companies who have paved the way forward in this field.
Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.
With the Delta variant driving over 100,000 new infections per day across the United States, the COVID-19 pandemic is far from over. While COVID continues to rage, infectious disease experts are not only battling the ongoing pandemic but are on the lookout for the next virulent threat.
Late in 2019, Fulton Bank launched a brand-new division to support emerging Life Science and Technology companies. Many traditional banks have historically shied away from these types of companies, which often operate in pre-revenue business models that are more complicated to assess. However, if successful, these companies represent some of the greatest potential for growth and economic impact.
BioHealth Capital Region Retains Strong Grip on No. 4 Spot of Top 10 U.S. Biopharma Hubs Eyes Third Spot by 2023
As a life sciences cluster, the BioHealth Capital Region is poised to become a top-three cluster in the Genetic Engineering & Biotechnology News (GEN) Top 10 Biopharma Clusters ranking on the strengths of early-stage companies becoming commercial successes and the construction of millions of square feet of new wet lab space.
The 7th annual BioHealth Capital Region (BHCR) Forum will be held virtually again in 2021 with a small change. This year the Forum will be split between two half-days held on September 13th and 14th. With the theme of “Big Bio…Big Data…Converging”, the Forum will bring together the top biotech and life science executives and expert speakers from across the industry, academia, healthcare, government, finance, and real estate development, among others, to discuss this emerging space in BioHealth.